DK3576740T3 - Cancerbehandling - Google Patents

Cancerbehandling Download PDF

Info

Publication number
DK3576740T3
DK3576740T3 DK18702299.1T DK18702299T DK3576740T3 DK 3576740 T3 DK3576740 T3 DK 3576740T3 DK 18702299 T DK18702299 T DK 18702299T DK 3576740 T3 DK3576740 T3 DK 3576740T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
DK18702299.1T
Other languages
Danish (da)
English (en)
Inventor
Kim Stuyckens
Porre Peter Marie Z De
Arlene O Siefker-Radtke
Anjali Narayan Avadhani
Yohann Loriot
Ruixo Juan Jose Perez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3576740(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Application granted granted Critical
Publication of DK3576740T3 publication Critical patent/DK3576740T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
DK18702299.1T 2017-02-06 2018-02-02 Cancerbehandling DK3576740T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
DK3576740T3 true DK3576740T3 (da) 2023-07-24

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18702299.1T DK3576740T3 (da) 2017-02-06 2018-02-02 Cancerbehandling

Country Status (25)

Country Link
US (2) US11077106B2 (enExample)
EP (2) EP4286005A3 (enExample)
JP (3) JP2020505425A (enExample)
KR (2) KR20190110581A (enExample)
CN (1) CN110198716A (enExample)
AU (2) AU2018216969B2 (enExample)
BR (1) BR112019016043A2 (enExample)
CA (1) CA3049737A1 (enExample)
DK (1) DK3576740T3 (enExample)
ES (1) ES2953005T3 (enExample)
FI (1) FI3576740T3 (enExample)
HR (1) HRP20230697T1 (enExample)
HU (1) HUE062453T2 (enExample)
IL (1) IL268463A (enExample)
JO (1) JOP20190190A1 (enExample)
LT (1) LT3576740T (enExample)
MX (2) MX2019009304A (enExample)
PH (1) PH12019501885A1 (enExample)
PL (1) PL3576740T3 (enExample)
RS (1) RS64778B1 (enExample)
SG (2) SG10202105110VA (enExample)
SI (1) SI3576740T1 (enExample)
SM (1) SMT202300233T1 (enExample)
TW (1) TWI874925B (enExample)
UA (1) UA126336C2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
SMT202200177T1 (it) 2014-09-26 2022-05-12 Janssen Pharmaceutica Nv Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA54932A (fr) * 2019-02-12 2021-12-22 Janssen Pharmaceutica Nv Traitement contre le cancer
WO2020205493A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3946340A1 (en) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2021220285A1 (en) * 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
PH12019501885A1 (en) 2020-06-29
EP3576740B1 (en) 2023-06-14
BR112019016043A2 (pt) 2020-03-31
CA3049737A1 (en) 2018-08-09
JOP20190190A1 (ar) 2019-08-04
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
JP2020505425A (ja) 2020-02-20
HRP20230697T1 (hr) 2023-10-13
US20200022976A1 (en) 2020-01-23
HUE062453T2 (hu) 2023-11-28
JP2025024064A (ja) 2025-02-19
US11077106B2 (en) 2021-08-03
EP4286005A3 (en) 2024-03-06
ES2953005T3 (es) 2023-11-07
AU2018216969B2 (en) 2024-04-11
EP3576740A1 (en) 2019-12-11
AU2018216969A1 (en) 2019-07-25
LT3576740T (lt) 2023-08-10
SI3576740T1 (sl) 2023-10-30
SG10202105110VA (en) 2021-06-29
FI3576740T3 (fi) 2023-08-31
AU2024201871A1 (en) 2024-04-11
EP4286005A2 (en) 2023-12-06
MX2022007955A (es) 2022-07-27
PL3576740T3 (pl) 2023-09-11
JP7668777B2 (ja) 2025-04-25
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
IL268463A (en) 2019-09-26
SMT202300233T1 (it) 2023-09-06
TWI874925B (zh) 2025-03-01
KR20190110581A (ko) 2019-09-30
MX2019009304A (es) 2019-09-19
CN110198716A (zh) 2019-09-03
RS64778B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
IL296080B1 (en) Method for treating cancer
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
IL255261A0 (en) Methods for treating cancer
EP3601536A4 (en) TREATMENT PROCESSES
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
PL3283527T3 (pl) Leczenie skojarzone nowotworów
IL284875A (en) Lasofoxifene treatment of breast cancer
HUE059694T2 (hu) Készítmény rák kezelésére
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
IL268463A (en) Cancer treatment
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265697B1 (en) Treatment of prostate cancer
PL3622953T3 (pl) Leczenie skojarzone nowotworu
IL264443A (en) Methods of treating prostate cancer
EP3546020C0 (en) CANCER TREATMENT DEVICE
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
EP3413927A4 (en) CANCER THERAPY
EP3593139C0 (en) CANCER BIOMARKERS
HUE040167T2 (hu) Rákkezelés
IL308399A (en) Methods of treating cancer
EP3597225A4 (en) TREATMENT PROCESS
IL281600A (en) Methods of treating cancer
EP3733175A4 (en) THERAPEUTICS AGAINST CANCER
IL281845A (en) Combination therapy for the treatment of cancer